

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- | | | |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | The statistical test(s) used AND whether they are one- or two-sided
<i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i> |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A description of all covariates tested |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> | For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
<i>Give P values as exact values whenever suitable.</i> |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> | Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study is available from Cuebiq through their COVID19 Data for Good program, but restrictions apply to the availability of these data, which were used under licenses for the current study, and so they are not publicly available. Information about how to request access to the data and its conditions and limitations can be found in <https://www.cuebiq.com/about/data-for-good/>. Source anonymized aggregated data and the code to reproduce our main results are publicly available on github: https://github.com/emoro/walking_COVID19

Other data used comes from the American Community Survey (5-year) from the Census, or the CDC 500 Cities datasets. See Supplementary Material for a description of them.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Our data does not come from a designed experiment. It was collected passively through geo-locations from anonymous opted-in devices collected by the company Cuebiq in 11 metro areas in the US. Data has been aggregated at the level of places, categories or census areas where a number of devices are present to prevent de-anonymization.
Research sample	The sample of users is that described above: anonymous opted-in devices collected by the company Cuebiq. This sample was used to comply with privacy regulations
Sampling strategy	We only selected users for which walking activity was detected at least in the period studied. For the aggregated results by census tract we only considered those census tracts with at least ten detected users living there. To minimize the potential bias of geographical penetration of our users, we have implemented post-stratification techniques. All details about our sampling method and post-stratification techniques can be found in the Supplementary Material
Data collection	Data was collected using the geo-location of the users by the Cuebiq company using the location provided by different applications in their mobile phones
Timing	Data was collected from February 2020 through June 2020
Data exclusions	No data was excluded in our analysis
Non-participation	Only anonymous opted-in devices were used in the analysis
Randomization	The data collected is observational and does not come from an experiment. Thus, this is not applicable.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involvement in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics

See above

Recruitment

Data used are geo-locations from anonymous opted-in devices collected by the company Cuebiq in 11 metro areas in the US. Data has been aggregated at the level of places, categories or census areas where a number of devices are present to prevent de-anonymization. We only selected users for which walking activity was detected at least in the period studied. For the aggregated results by census tract we only considered those census tracts with at least ten detected users living there. To minimize the potential bias of geographical penetration of our users, we have implemented post-stratification techniques. All details about our sampling method and post-stratification techniques can be found in the Supplementary Material

Ethics oversight

The privacy-enhanced mobility data were collected by Cuebiq using anonymized records of GPS locations from users that opted-in to share the data anonymously through a General Data Protection Regulation (GDPR) and California Consumer Privacy Act (CCPA) compliant framework. Additionally, we obtained IRB exemption to use the mobility data from the MIT IRB office through protocols #1812635835 and its extension #E-2962. Specifically, our study activities were "considered exempt after review by the Committee on the Use of Humans as Experimental Subjects to Federal regulations"

Note that full information on the approval of the study protocol must also be provided in the manuscript.